Bill Text: IL SR0737 | 2023-2024 | 103rd General Assembly | Introduced
Bill Title: Recognizes February 18, 2024 as being World Cholangiocarcinoma Day.
Spectrum: Partisan Bill (Democrat 1-0)
Status: (Passed) 2024-05-25 - Resolution Adopted [SR0737 Detail]
Download: Illinois-2023-SR0737-Introduced.html
| |||||||
| |||||||
1 | SENATE RESOLUTION | ||||||
2 | WHEREAS, Cholangiocarcinoma (bile duct cancer) is a rare | ||||||
3 | form of cancer that originates from the cells lining the bile | ||||||
4 | ducts that play a key role in digestion; there are three types | ||||||
5 | of this cancer, intrahepatic, extrahepatic, and perihilar; and
| ||||||
6 | WHEREAS, Approximately 12,000 Americans are diagnosed each | ||||||
7 | year with cholangiocarcinoma, with numbers increasing yearly, | ||||||
8 | and the mortality rate has increased dramatically in the last | ||||||
9 | decade; and
| ||||||
10 | WHEREAS, Patients are typically diagnosed at a late stage | ||||||
11 | due to the lack of a validated early method of detection; | ||||||
12 | symptoms of jaundice, abdominal pain, itchy skin, and weight | ||||||
13 | loss are symptoms that do not usually present until advanced | ||||||
14 | disease progression; and
| ||||||
15 | WHEREAS, Cholangiocarcinoma is a rare cancer; of the top | ||||||
16 | eight deadliest cancers, seven are rare; rare cancers have a | ||||||
17 | five-year survival rate under 50%, with the cholangiocarcinoma | ||||||
18 | five-year survival rate being approximately 20%; and
| ||||||
19 | WHEREAS, There is currently no cure for | ||||||
20 | cholangiocarcinoma/bile duct cancer; and
|
| |||||||
| |||||||
1 | WHEREAS, Kelly green is the color representing | ||||||
2 | cholangiocarcinoma/bile duct cancer awareness; and
| ||||||
3 | WHEREAS, Foundations, research and teaching hospitals, | ||||||
4 | rare cancer advocate groups, and patient advocate groups from | ||||||
5 | around the globe have joined together to recognize February | ||||||
6 | 18, 2024 as World Cholangiocarcinoma Day; and
| ||||||
7 | WHEREAS, Increased cholangiocarcinoma advocacy, | ||||||
8 | awareness, research, and education will bring improved | ||||||
9 | outcomes for patients in earlier detection and treatment and | ||||||
10 | potential curative methods; therefore, be it
|